208 related articles for article (PubMed ID: 25075869)
1. Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.
Gerson JE; Castillo-Carranza DL; Kayed R
ACS Chem Neurosci; 2014 Sep; 5(9):752-69. PubMed ID: 25075869
[TBL] [Abstract][Full Text] [Related]
2. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
3. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
[TBL] [Abstract][Full Text] [Related]
4. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.
Marcus JN; Schachter J
J Neurogenet; 2011 Dec; 25(4):127-33. PubMed ID: 22091726
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Approaches Targeting Pathological Tau Aggregates.
Gerson J; Kayed R
Curr Pharm Des; 2016; 22(26):4028-39. PubMed ID: 27189598
[TBL] [Abstract][Full Text] [Related]
6. What is the pathological significance of tau oligomers?
Cowan CM; Quraishe S; Mudher A
Biochem Soc Trans; 2012 Aug; 40(4):693-7. PubMed ID: 22817718
[TBL] [Abstract][Full Text] [Related]
7. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
8. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders.
Kayed R; Jackson GR
Curr Opin Immunol; 2009 Jun; 21(3):359-63. PubMed ID: 19482462
[TBL] [Abstract][Full Text] [Related]
9. Proteolytic processing of tau.
Wang Y; Garg S; Mandelkow EM; Mandelkow E
Biochem Soc Trans; 2010 Aug; 38(4):955-61. PubMed ID: 20658984
[TBL] [Abstract][Full Text] [Related]
10. Invited review: Drug development for tauopathies.
Grüninger F
Neuropathol Appl Neurobiol; 2015 Feb; 41(1):81-96. PubMed ID: 25354646
[TBL] [Abstract][Full Text] [Related]
11. Granular tau oligomers as intermediates of tau filaments.
Maeda S; Sahara N; Saito Y; Murayama M; Yoshiike Y; Kim H; Miyasaka T; Murayama S; Ikai A; Takashima A
Biochemistry; 2007 Mar; 46(12):3856-61. PubMed ID: 17338548
[TBL] [Abstract][Full Text] [Related]
12. Tau aggregates as immunotherapeutic targets.
Castillo-Carranza DL; Lasagna-Reeves CA; Kayed R
Front Biosci (Schol Ed); 2013 Jan; 5(2):426-38. PubMed ID: 23277060
[TBL] [Abstract][Full Text] [Related]
13. Tau-based therapies in neurodegeneration: opportunities and challenges.
Li C; Götz J
Nat Rev Drug Discov; 2017 Dec; 16(12):863-883. PubMed ID: 28983098
[TBL] [Abstract][Full Text] [Related]
14. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.
Clavaguera F; Grueninger F; Tolnay M
Neuropharmacology; 2014 Jan; 76 Pt A():9-15. PubMed ID: 24050961
[TBL] [Abstract][Full Text] [Related]
15. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies.
Zilka N; Kontsekova E; Novak M
J Alzheimers Dis; 2008 Oct; 15(2):169-79. PubMed ID: 18953106
[TBL] [Abstract][Full Text] [Related]
16. From tau phosphorylation to tau aggregation: what about neuronal death?
Buée L; Troquier L; Burnouf S; Belarbi K; Van der Jeugd A; Ahmed T; Fernandez-Gomez F; Caillierez R; Grosjean ME; Begard S; Barbot B; Demeyer D; Obriot H; Brion I; Buée-Scherrer V; Maurage CA; Balschun D; D'hooge R; Hamdane M; Blum D; Sergeant N
Biochem Soc Trans; 2010 Aug; 38(4):967-72. PubMed ID: 20658986
[TBL] [Abstract][Full Text] [Related]
17. Production of recombinant tau oligomers in vitro.
Combs B; Tiernan CT; Hamel C; Kanaan NM
Methods Cell Biol; 2017; 141():45-64. PubMed ID: 28882311
[TBL] [Abstract][Full Text] [Related]
18. Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain.
Sahara N; Maeda S; Yoshiike Y; Mizoroki T; Yamashita S; Murayama M; Park JM; Saito Y; Murayama S; Takashima A
J Neurosci Res; 2007 Nov; 85(14):3098-108. PubMed ID: 17628496
[TBL] [Abstract][Full Text] [Related]
19. The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.
Deger JM; Gerson JE; Kayed R
Aging Cell; 2015 Oct; 14(5):715-24. PubMed ID: 26053162
[TBL] [Abstract][Full Text] [Related]
20. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.
Lo CH; Lim CK; Ding Z; Wickramasinghe SP; Braun AR; Ashe KH; Rhoades E; Thomas DD; Sachs JN
Alzheimers Dement; 2019 Nov; 15(11):1489-1502. PubMed ID: 31653529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
